Remove news cardiovascular
article thumbnail

#news #biotech AstraZeneca punts midphase cardiovascular prospect to startup

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: AstraZeneca punts midphase cardiovascular prospect to startup.AstraZeneca punts midphase cardiovascular prospect to startup ntaylor Thu, 02/03/2022 – 05:32 from FierceBiotech: Biotech [link].

article thumbnail

#news #biotech PhaseBio blames COVID-19 disruption as cardiovascular study axed

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: PhaseBio blames COVID-19 disruption as cardiovascular study axed.PhaseBio blames COVID-19 disruption as cardiovascular study axed aarmstrong Tue, 12/21/2021 – 09:20 from FierceBiotech: Biotech [link].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

#news #biotech Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet.Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet ntaylor Wed, 11/24/2021 – 08:23 from FierceBiotech: Biotech [link].

article thumbnail

#news #biotech 89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data set

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: 89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data set.89bio, 89bio, trying to rise from ashes of NASH … Continue reading →

article thumbnail

#news #biotech Novo Nordisk puts $1.2B on the table for Prothena’s ATTR drug, teeing up Alnylam challenge and cardiovascular expansion

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Novo Nordisk puts $1.2B on the table for Prothena’s ATTR drug, teeing up Alnylam challenge and cardiovascular expansion.Novo Nordisk puts $1.2B on the table for Prothena’s ATTR … Continue reading →

Drugs 40
article thumbnail

Novartis reveals vital Leqvio data

Pharma Times

The therapy involves treating individuals with atherosclerotic cardiovascular disease - News - PharmaTimes

104
104
article thumbnail

Wegovy Obesity Drug Could Offer Heart Benefits According to Latest Trial Data

XTalks

Novo presented the results of the study at the American Heart Association (AHA) Scientific Sessions this past weekend in Philadelphia, which were also published in the New England Journal of Medicine. However, the results did not suggest that Wegovy specifically reduces the risk of cardiovascular death.

Trials 104